MDxHealth S.A. (MDXH) Stock Analysis & Investment Frameworks
MDxHealth S.A. (MDXH) stock analysis on Invetso. Review MDxHealth S.A.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
MDxHealth S.A. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: BE
MDxHealth S.A. Key Financial Metrics
- Market Cap: $14.92M
- Revenue: $107.88M
- ROE: 142.63%
- ROIC: -16.67%
- Dividend Yield: N/A
About MDxHealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDxHealth S.A. Investment Frameworks
Invetso analyzes MDxHealth S.A. (MDXH) across the following frameworks:
- MDxHealth S.A. 10Y Growth Potential
- MDxHealth S.A. Scenario Analysis
- MDxHealth S.A. Risks & Opportunities
- MDxHealth S.A. Economic Moat
- MDxHealth S.A. Business Model
- MDxHealth S.A. Management
- MDxHealth S.A. SWOT Analysis
- MDxHealth S.A. Porter's 5 Forces
- MDxHealth S.A. PESTLE Analysis
- MDxHealth S.A. ESG Analysis